Prelude Therapeutics FY2025 net loss narrows to $99.5M; cash $106.4M; IND cleared for PRT12396

Prelude Therapeutics Inc

Net loss of $99.5M ($1.29/share) improved from $127.2M ($1.68/share) in 2024.
Cash, equivalents and marketable securities $106.4M as of Dec 31, 2025; runway into Q2 2027.
FDA cleared IND for PRT12396 (mutant-selective JAK2V617F inhibitor); Phase 1 start expected Q2 2026.
KAT6A degrader PRT13722 IND filing planned mid-2026; Phase 1 initiation in H2 2026.
Exclusive option agreement with Incyte for JAK2 program (Nov 2025); DAC collaboration with AbCellera expanded.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Prelude Therapeutics Inc reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the full year ended December 31, 2025

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0001193125-26-099424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.